Dynamic alterations in the irradiated draining lymph node
- 1Laboratory for Applied Radiobiology, University of Zurich, Zurich, Switzerland
- 2Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
- 3Institute of Immunobiology, Medical Research Center, Cantonal Hospital St.Gallen, St. Gallen, Switzerland
Abstract
Tumor-draining lymph nodes (DLNs) are crucial for the development of anti-tumor immunity upon irradiation. However, in radiotherapy, DLNs are frequently co-irradiated, which impairs their function. Here, we examine the consequences of DLN irradiation on anti-tumor immunity, focusing on the recently described radiotherapy-induced disruption of the CCR7-CCL19/CCL21 axis, which governs tumor-to-DLN trafficking. We use in vivo irradiated murine LNs and in vitro assays to assess irradiation-induced structural and functional changes in the DLNs. DLN-infiltrating lymphocytes and CCL19/CCL21 chemokines were depleted early after irradiation in a dose-dependent manner. Lymphocyte numbers recovered only in DLNs irradiated with 5 Gy or less. Lymphopenia persisted in DLNs irradiated with 15 Gy, with few surviving lymphocytes showing a compensatory increase in proliferation. Irradiation-deregulated secretion of CCL19 could be related to lymphodepletion and/or direct irradiation-induced processes in stromal cells. In conclusion, radiotherapy depletes DLNs, and impairs stromal function and chemokine signaling, thereby compromising anti-tumor immunity.
Related
- Multimodal radiomics based on dynamic contrast-enhanced ultrasound for predicting cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto’s thyroiditis
- Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy
- Immune remodeling of breast tumor-draining lymph nodes: antigen-presenting cell dysfunction, regulatory T-cell expansion, and premetastatic niche formation
- Neoadjuvant treatment is associated with fibrotic and transcriptional remodeling of tumor-draining lymph nodes in rectal cancer
- Single-cell analyses reveal lymph node-tumor ecosystem remodeling during lymph node metastasis of gastric cancer
BibTeX
@article{reichl2026dynamic,
title = {{Dynamic alterations in the irradiated draining lymph node}},
author = {Sabrina Reichl and Lisa Kurz and Alba Sanchez Fernandez and Elina Bugar and Irene Vetrugno and Burkhard Ludewig and Martin Pruschy and Irma Telarovic},
journal = {NPJ Precision Oncology},
year = {2026},
month = jul,
doi = {10.1038/s41698-026-01610-y},
url = {https://doi.org/10.1038/s41698-026-01610-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dynamic alterations in the irradiated draining lymph node
AU - Sabrina Reichl
AU - Lisa Kurz
AU - Alba Sanchez Fernandez
AU - Elina Bugar
AU - Irene Vetrugno
AU - Burkhard Ludewig
AU - Martin Pruschy
AU - Irma Telarovic
PY - 2026
DA - 2026/07/11
JO - NPJ Precision Oncology
DO - 10.1038/s41698-026-01610-y
UR - https://doi.org/10.1038/s41698-026-01610-y
AB - Tumor-draining lymph nodes (DLNs) are crucial for the development of anti-tumor immunity upon irradiation. However, in radiotherapy, DLNs are frequently co-irradiated, which impairs their function. Here, we examine the consequences of DLN irradiation on anti-tumor immunity, focusing on the recently described radiotherapy-induced disruption of the CCR7-CCL19/CCL21 axis, which governs tumor-to-DLN trafficking. We use in vivo irradiated murine LNs and in vitro assays to assess irradiation-induced structural and functional changes in the DLNs. DLN-infiltrating lymphocytes and CCL19/CCL21 chemokines were depleted early after irradiation in a dose-dependent manner. Lymphocyte numbers recovered only in DLNs irradiated with 5 Gy or less. Lymphopenia persisted in DLNs irradiated with 15 Gy, with few surviving lymphocytes showing a compensatory increase in proliferation. Irradiation-deregulated secretion of CCL19 could be related to lymphodepletion and/or direct irradiation-induced processes in stromal cells. In conclusion, radiotherapy depletes DLNs, and impairs stromal function and chemokine signaling, thereby compromising anti-tumor immunity.
SN - 2397-768X
ER -